What are the side effects of Jakavi 10mg tablet?

Jakavi 10mg tablet cause several side effects such as fiver, muscle pain, diarrhea, vomiting, joint pain and skin rash. Consult the healthcare professional if any of the symptoms persist.

Can heart patient use Jakavi 10mg tablet?

There are no general guidelines found in the search results. The use of Jakavi 10mg tablet must be determined by the doctor.

Is Jakavi 10mg tablet taken with other medication as well?

Jakavi 10mg tablet is always intended for use in combination with other medications; consult with a healthcare professional.

What is the active ingredient of Jakavi 10mg tablet?

Jakavi 10mg tablet salt formation is Ruxolitinib which helps to improve blood cancer such as chronic idiopathic myelofibrosis and polycythemia

Buy Jakavi 10mg Tablet Online: Price, 5% Discount, Uses, and Side Effects

Name: Jakavi 10mg Tablet
Brand: Jakavi
Price: 39999 INR
Availability: InStock
Rating: 5 (7 reviews)

Description

Jakavi 10mg tablet is an anti-cancer medication. It is prescription based medication used mainly for blood disorders like myelofibrosis and polycythemia vera.Its active ingredient is Ruxolitinib which belongs to the group of janus kinase inhibitors.

It works by inhibiting the JAK enzymes, which play a key role in abnormal cell signaling and inflammation. By blocking these enzymes.

Ruxolitinib helps reduced uncontrolled cell growth, inflammation and related symptoms in blood disorders. Doctor's prescription is required for the treatment to ensure safe and effective treatment.

Uses

Treat blood disorders, including myelofibrosis and polycythemia vera

Side Effects

Every medication has several side effects that are harmful to the body if not treated early. If you experience any of the symptoms, visit the doctor immediately to avoid complications during the treatment. Common ones include:

Low red and white blood cell counts
Low platelet counts
Dizziness, headache
Bruising
Diarrhea
Infections, including viral infections
Swelling in the face and body
Fatigue or tiredness

Severe infections like hepatitis B
Anemia
Bleeding

How To Use

Jakavi 10mg tablet should be taken with or without food at the fixed time everyday as recommended by the healthcare professional.
Do not crush, break, or chew the tablet just swallow it whole glass of water.
The doctor will decide the correct dosage and duration based on the patient's height, weight and response to the treatment.
Always take the tablet according to the healthcare professional.

How It Works

Jakavi 10mg tablet works by inhibiting the JAK1 and JAK2 enzyme, which are involved in signaling pathways that regulate blood cell production and immune activity. By blocking the enzymes it helps reduce abnormal cell growth, lower inflammation and shrink enlarged spleens.

Thereby improving disease related symptoms and overall quality of life in affected patients.

Safety Advice

Alcohol

If you are an alcoholic, avoid using it as it interferes with the treatment when using Jakavi 10mg tablet.

Pregnancy

Pregnant women should avoid using Jakavi 10mg tablet because it may interrupt with the pregnancy symptoms and harm the fetus in several ways.

Breast Feeding

Jakavi 10mg tablet is not recommended for breastfeed women as the tablet is passed through breast which is harmful for the baby.

Driving

Jakavi 10mg tablet may cause dizziness and loss of vision ability. Consult with the doctor for proper medical attention.

Kidney

Kidney patients must consult the doctor before using Jakavi 10mg tablet. It may interfere with the kidney function.

Liver

The Jakavi 10mg tablet should disrupt the liver function. It can be correctly administered by a healthcare professional.

FAQs

Jakavi 10mg tablet should be taken by the patient of blood disorder such as chronic idiopathic myelofibrosis and polycythemia

References

Mascarenhas, J., & Hoffman, R. (2012). Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clinical cancer research, 18(11), 3008-3014. https://pubmed.ncbi.nlm.nih.gov/22474318/
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., ... & Kantarjian, H. M. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366(9), 799-807. https://pubmed.ncbi.nlm.nih.gov/22375971/
Elli, E. M., Baratè, C., Mendicino, F., Palandri, F., & Palumbo, G. A. (2019). Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Frontiers in oncology, 9, 1186.
Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., ... & Verstovsek, S. (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New England Journal of Medicine, 372(5), 426-435.
Harrison, C., Kiladjian, J. J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., ... & Barosi, G. (2012). JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine, 366(9), 787-798

Jakavi 10mg Tablet

About The Product